While clearly lagging behind their US counterparts, European biotechnology companies and medtech firms across all stages of development can still attract significant venture capital if they are innovative enough.
That is what Olivier Litzka of Edmond De Rothschild Investment Partners (EdRIP) told Scrip as the Paris-based finance house unveiled...